Who
Jonathan Gillis
CAO and Interim CFO
Company insider
Files Form 4 as: CAO and Interim CFO, MapLight Therapeutics; Senior Vice President, Finance, Tempest Therapeutics.
In numbers
- Trades disclosed
- 46
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $7.2M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 21 Jun 2017
- Last trade
- 15 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Apr – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 16 Oct 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $82K10,167 at $8.08 | filing |
| 17 Aug 2026filed 19 Aug 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,020 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,222 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | MPLT MapLight Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,455 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | MPLT MapLight Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,455 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | MPLT MapLight Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,813 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | MPLT MapLight Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,813 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,020 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,222 at $0.00 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K600 at $36.51 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $638K16,969 at $37.61 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $34K900 at $38.17 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K600 at $36.51 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $638K16,969 at $37.61 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $34K900 at $38.17 | filing |
| 16 Jul 2026filed 20 Jul 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $256K6,979 at $36.66 | filing |
| 16 Jul 2026filed 20 Jul 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $55K1,476 at $37.44 | filing |
| 16 Jul 2026filed 20 Jul 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $256K6,979 at $36.66 | filing |
| 16 Jul 2026filed 20 Jul 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $55K1,476 at $37.44 | filing |
| 15 Jul 2026filed 20 Jul 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Sold | $194K5,356 at $36.13 | filing |
News
No headline names them, or the companies they trade most, lately.